Background: The Centers for Disease Control and Prevention (CDC) and US Preventive Services Task Force recommend routine HIV screening for adolescents and adults. Recently, the Denver HIV Risk Score (DHRS) was developed as a clinical prediction instrument to guide HIV screening by providing estimates of HIV infection risk. The DHRS has been refined to include only patient demographics, sex with a male, injection drug use, and past HIV test, but has not been broadly validated across different geographic regions or HIV testing venues. Our purpose was to externally validate the refined DHRS in a national HIV testing cohort from the CDC. Methodology: This was a secondary analysis of HIV testing data from the Program Evaluation and Monitoring System of the CDC’s National HIV Prevention Program. Data from all CDC-funded HIV testing sites in the U.S. with the exception of Massachusetts, North Dakota, Ohio and Rhode Island were included. Individuals ≥13 years of age who underwent HIV testing from January 1, 2008 through December 31, 2010 were used with newly-diagnosed HIV infection as the outcome. All observations were assigned scores according to the refined DHRS and categorized into 5 mutually exclusive groups: < 20 (very low risk); 20-29 (low risk); 30-39 (moderate risk); 40-49 (high risk); and ≥50 (very high risk). Proportions and 95% CIs for each group are reported. Calibration is reported as predicted versus observed HIV prevalence and discrimination is reported using a ROC curve and the areas under the curve. Results: 4,830,941 testing events occurred, resulting in 30,080 (0.6%) newly-identified HIV infections. Of all visits, 432,674 (9%) were categorized as very low risk with an HIV prevalence of 0.20% (95% CI: 0.19%-0.21%), 1,312,427 (27%) were low risk with a prevalence of 0.17% (95% CI: 0.16%-0.17%), 2,003,857 (41%) were moderate risk with a prevalence of 0.39% (95% CI: 0.38%-0.40%), 811,501 (17%) were high risk with a prevalence of 1.19% (95% CI: 1.16%-1.21%), and 270,482 (6%) were very high risk with a prevalence of 3.57% (95% CI: 3.50%-3.64%). The DHRS demonstrated excellent calibration (regression slope = 1.09; R2 = 0.99), good discrimination (ROC area = 0.77, 95% CI: 0.77 - 0.77), and similar accuracy across geographic regions. Conclusions: The refined DHRS accurately categorized patients into significantly different HIV risk groups, regardless of geographic region. The refined DHRS is a relatively simple tool for quantifying HIV risk and may help identify individuals for HIV testing.